Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THRILL anakinra for hyperinflammation in pediatric oncology sepsis
NL-OMON61133Phase 2Not yet recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- May 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of anakinra in sepsis, cytokine release syndrome (CRS), sponsored by Princess Máxima Center for Pediatric Oncology. Planned start May 2026; status: not yet recruiting.
02
Drugs
anakinra
03
Conditions
sepsiscytokine release syndrome (CRS)
Beyond the preview
Go deeper on NL-OMON61133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61133.